EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Abstract
Purpose: Epidermal growth factor receptor (EGFR) and VEGF(R) signaling show extensive cross-talk, providing a rationale for joint targeting of the two pathways. However, combinations of monoclonal antibodies (mAb) targeting EGFR and VEGF showed disappointing activity in patients with colorectal cancer (CRC). We speculated that inhibition of surface receptors and ligands might only partly prevent oncogenic signaling whereas small-molecule tyrosine kinase inhibitors (TKI) would also influence intracellular signaling. Experimental Design: Mice with CRC xenografts were treated with two TKIs, vargatef and afatinib, or with two mAbs, bevacizumab and cetuximab, and their influence on tumor growth, viability, in vivo DNA synthesis, and the presence of phosphorylated EGFR and VEGFR was determined. The activity of the TKIs was further characterized in CRC cells with different KRAS status. Results: Vargatef and afatinib together showed strong tumor growth inhibition toward HT-29 xenografts compared with either drug alone, which was associated with a 5-fold increase in apoptotic tumor cell death. In comparison, bevacizumab and cetuximab together were exclusively cytostatic with no more activity than either drug alone. Exposure to the two TKIs was accompanied by a marked decrease of tumor-associated intracellular phospho-VEGFR1 and phospho-EGFR, whereas similar exposure to the two mAbs had no detectable effect. A synergistic activity of vargatef plus afatinib was observed in all eight CRC cell lines examined, independent of KRAS status. Conclusions: Our results indicate that attenuation of intracellular EGFR and/or VEGF signaling is required for cytotoxic activity. These findings provide a rationale for trials of the TKIs, even in patients with mutant KRAS. Clin Cancer Res; 17(20); 6522–30. ©2011 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in another preclinical study, the combination of bevacizumab and cetuximab did not increase apoptotic tumor cell death compared to either drug alone [62].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [62]
In the citing paper
“However, in another study, the use of bevacizumab and cetuximab together did not have a greater increase in apoptotic tumour cell death compared to either drug alone [152].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [152]
Citations
Cites
1 retracted
Ling, Y., Li, T., Yuan, Z., Haigentz, M., Weber, T. K., & Perez-Soler, R. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.034827 · Cited by 75
RetractedCell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“Drug combination effects were determined by the analysis of Chou and Talalay based on the median-effect equation (23, 24) and are indicated in terms of combination index.”
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,341
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Saltz, L. B., Lenz, H.-J., Kindler, H. L., Hochster, H. S., Wadler, S., Hoff, P. M., Kemeny, N. E., Hollywood, E. M., Gonen, M., Quinones, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0949 · Cited by 425
Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., Placido, S. D., Bianco, A. R., Mendelsohn, J. M., & Tortora, G. (2000) · PubMed · Cited by 378
Cited by
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
Thomas, R., & Weihua, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00800 · Cited by 201
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Tournigand, C., Chibaudel, B., Samson, B., Scheithauer, W., Vernerey, D., Mésange, P., Lledo, G., Viret, F., Ramée, J., Tubiana-Mathieu, N., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00216-8 · Cited by 137
Self-citationZhang, Y., Schwerbrock, N. M. J., Rogers, A. B., Kim, W. Y., & Huang, L. (2013) · Molecular Therapy · doi:10.1038/mt.2013.120 · Cited by 126
Metadata
- Authors
- Poindessous, V., Ouaret, D., El Ouadrani, K., Battistella, A., Mégalophonos, V. F., Kamsu-Kom, N., Petitprez, A., Escargueil, A. E., Boudou, P., Dumont, S., Cervera, P., Fléjou, J.-F., André, T., Tournigand, C., Chibaudel, B., de Gramont, A., & Larsen, A. K.
- Affiliations
- Inserm (FR)
- Authors' Affiliations: 1Laboratory of Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine; 2Institut National de la Santé et de la Recherche Médicale U938; 3Université Pierre et Marie Curie (University of Paris 6); Departments of 4Pathology and 5Clinical Oncology, Hôpital Saint-Antoine, Paris, France
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2011-10-14
- Volume
- 17
- Issue
- 20
- Pages
- 6522-6530
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2171406886
- Cited by
- 55
- References
- 39
- Citations by year
- 2026: 2 · 2024: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 7 · 2015: 10 · 2014: 9 · 2013: 7 · 2012: 4
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- colorectal cancer, EGFR, VEGFR, tyrosine kinase inhibitors, afatinib, bevacizumab, cetuximab, monoclonal antibodies, drug synergy, KRAS status, apoptosis, xenograft models
- MeSH terms
- Bevacizumab, Cetuximab, Afatinib, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Drug Synergism, Female, Humans, Indoles, Mice, Nude, Protein-Tyrosine Kinases, Quinazolines, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, HT29 Cells, Xenograft Model Antitumor Assays, Receptors, Vascular Endothelial Growth Factor, Cell Proliferation, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-1607
- The paper
- Poindessous, V., Ouaret, D., El Ouadrani, K., Battistella, A., Mégalophonos, V. F., Kamsu-Kom, N., Petitprez, A., Escargueil, A. E., Boudou, P., Dumont, S., Cervera, P., Fléjou, J.-F., André, T., Tournigand, C., Chibaudel, B., de Gramont, A., & Larsen, A. K. (2011). EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-1607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.